System Evaluation of Buyang Huanwu Decoction in Treatment of Acute Ischemic Stroke

Tang, Qiang; ZHANG, Shiqiang; Zhu, Luwen; Tang, Yizhou; Li, Hongyu

doi:10.3724/sp.j.1329.2021.06011

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Western medicine treatment of IS includes aspirin and clopidogrel antiplatelet aggregation drugs, and thrombolysis [15] . Traditional Chinese medicine mainly focuses on nourishing Qi and strengthening the body, promoting blood circulation, removing stasis, and dredging collaterals [16] . QLC is a drug approved by the Chinese Food and Drug Administration for the treatment of IS, primarily for IS due to lack of air and blood stasis syndrome [17] .…”

Section: Discussionmentioning

confidence: 99%

Qilong capsule alleviates ponatinib-induced ischemic stroke in a zebrafish model by regulating coagulation, inflammation, and apoptosis

Lin¹,

Liu²,

Sun³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Qilong capsule (QLC) is a traditional Chinese medicine commonly used to treat ischemic stroke (IS). But the pharmacodynamic mechanism of QLC is not clear. Method: we used an existing zebrafish model to explore the protective mechanism of QLC on IS. We treated normally-developing zebrafish larvae with QLC and ponatinib 2 days post fertilization, and used the area of cerebral vascular thrombosis, red blood cell staining intensity, and brain cell apoptosis to quantitate QLC efficacy against IS. Real-time quantitative polymerase chain reaction (qPCR) was used to detect changes in the expression of genes involved in coagulation, inflammation, vascular endothelium, and apoptosis. Result: We found that QLC reduced the area affected by ponatinib-induced cerebral vascular embolism, erythrocyte staining intensity, and the number of apoptotic brain cells. qPCR showed that QLC inhibited the expression of genes related to coagulation, inflammation, and apoptosis. Conclusion: QLC had a significant protective efficacy in ponatinib-induced IS.

show abstract

Section: Discussionmentioning

confidence: 99%